Letters
Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation

https://doi.org/10.1016/j.jacc.2016.04.026Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

Please note: Dr. Gersh has consulted for Janssen Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.